Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Benjamin Ungar; Ana B. Pavel; Randall Li; Grace Kimmel; John Nia; Peter Hashim; Hee Jin Kim; Margot Chima; Anjali S. Vekaria; Yeriel Estrada; Hui Xu; Xiangyu Peng; Giselle K. Singer; Danielle Baum; Yasaman Mansouri; Mark Taliercio; Emma Guttman-Yassky

doi:10.1016/j.jaci.2020.04.055

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Benjamin Ungar
, Ana B. Pavel
, Randall Li
, Grace Kimmel
, John Nia
, Peter Hashim
, Hee Jin Kim
, Margot Chima
, Anjali S. Vekaria
, Yeriel Estrada
, Hui Xu
, Xiangyu Peng
, Giselle K. Singer
, Danielle Baum
, Yasaman Mansouri
, Mark Taliercio
, Emma Guttman-Yassky

Research output: Contribution to journal › Article › peer-review

99 Scopus citations

Original language	English
Pages (from-to)	394-397
Number of pages	4
Journal	Journal of Allergy and Clinical Immunology
Volume	147
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2020.04.055
State	Published - Jan 2021

Access to Document

10.1016/j.jaci.2020.04.055

Cite this

Ungar, B., Pavel, A. B., Li, R., Kimmel, G., Nia, J., Hashim, P., Kim, H. J., Chima, M., Vekaria, A. S., Estrada, Y., Xu, H., Peng, X., Singer, G. K., Baum, D., Mansouri, Y., Taliercio, M., & Guttman-Yassky, E. (2021). Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. Journal of Allergy and Clinical Immunology, 147(1), 394-397. https://doi.org/10.1016/j.jaci.2020.04.055

@article{eb2ee29bfdb846468827b823178d071e,

title = "Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis",

author = "Benjamin Ungar and Pavel, \{Ana B.\} and Randall Li and Grace Kimmel and John Nia and Peter Hashim and Kim, \{Hee Jin\} and Margot Chima and Vekaria, \{Anjali S.\} and Yeriel Estrada and Hui Xu and Xiangyu Peng and Singer, \{Giselle K.\} and Danielle Baum and Yasaman Mansouri and Mark Taliercio and Emma Guttman-Yassky",

note = "Funding Information: This study was funded by Novartis Pharmaceuticals Company . Funding Information: This study was funded by Novartis Pharmaceuticals Company.",

year = "2021",

month = jan,

doi = "10.1016/j.jaci.2020.04.055",

language = "English",

volume = "147",

pages = "394--397",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "1",

}

Ungar, B, Pavel, AB, Li, R, Kimmel, G, Nia, J, Hashim, P, Kim, HJ, Chima, M, Vekaria, AS, Estrada, Y, Xu, H, Peng, X, Singer, GK, Baum, D, Mansouri, Y, Taliercio, M & Guttman-Yassky, E 2021, 'Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis', Journal of Allergy and Clinical Immunology, vol. 147, no. 1, pp. 394-397. https://doi.org/10.1016/j.jaci.2020.04.055

TY - JOUR

T1 - Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

AU - Ungar, Benjamin

AU - Pavel, Ana B.

AU - Li, Randall

AU - Kimmel, Grace

AU - Nia, John

AU - Hashim, Peter

AU - Kim, Hee Jin

AU - Chima, Margot

AU - Vekaria, Anjali S.

AU - Estrada, Yeriel

AU - Xu, Hui

AU - Peng, Xiangyu

AU - Singer, Giselle K.

AU - Baum, Danielle

AU - Mansouri, Yasaman

AU - Taliercio, Mark

AU - Guttman-Yassky, Emma

N1 - Funding Information: This study was funded by Novartis Pharmaceuticals Company . Funding Information: This study was funded by Novartis Pharmaceuticals Company.

PY - 2021/1

Y1 - 2021/1

UR - https://www.scopus.com/pages/publications/85087308121

U2 - 10.1016/j.jaci.2020.04.055

DO - 10.1016/j.jaci.2020.04.055

M3 - Article

C2 - 32428528

AN - SCOPUS:85087308121

SN - 0091-6749

VL - 147

SP - 394

EP - 397

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -